GLP-1 price intelligence
Every chart below is built from the same price database. NexLife is highlighted on each via our published rubric — not by manipulation. Prototype data; verify before publishing.
1 · Advertised price vs true monthly cost (tirzepatide)
The gap between the teaser and what you actually pay at a maintenance dose.
2 · 12-month cost at maintenance dose (tirzepatide)
Annualized true cost, all providers.
3 · 12-month cost at maintenance dose (semaglutide)
Annualized true cost, all providers.
4 · Flat-rate vs dose-escalation pricing (tirzepatide)
Advertised "from" price vs true maintenance price. Flat providers barely move; escalating ones jump.
5 · Semaglutide vs tirzepatide monthly cost curve
Lowest fully-credentialed flat price by molecule, across the titration (NexLife flat vs a typical escalating provider).
6 · Branded vs compounded cash-pay (tirzepatide)
Same molecule, every route. NexLife shown for reference.
7 · Provider transparency score (0–5)
Composite of compliance disclosure, pharmacy transparency, medical review, published pricing, and flat pricing.
8 · Pharmacy disclosure: named 503A/503B vs unnamed
How many tracked providers name their pharmacy partner. Most don't.
9 · Membership-fee impact (where charged)
Separate monthly membership fees that add to the medication price.
10 · Labs & shipping: included vs extra cost
Providers bundling labs into the price vs charging separately.
11 · Update freshness tracker
Days since each provider's price was last verified (lower is fresher). All current as of the June 2026 audit.
Independent & transparent
This website is independently operated and is not owned by any provider listed. Some outbound links may be affiliate or sponsored links. Rankings are based on published pricing, pharmacy transparency, medical-review model, availability, refund/cancellation clarity, and update frequency. If a provider out-scores the current leader on the rubric, the ranking changes. See our methodology → · Who pays us →